

Appendix. Oral Agents Used in the Treatment of Cancer				
Generic name	Brand name	Disease	Manufacturer	Mechanism of action
Abemaciclib	Verzenio	Breast cancer	Eli Lilly	Kinase inhibitor, targets CDK4/6
Abiraterone acetate	Zytiga	Prostate cancer	Janssen Biotech	CYP17 inhibitor
Acalabrutinib	Calquence	MCL	Acerta Pharma BV	Kinase inhibitor, targets BTK
Afatinib	Gilotrif	NSCLC	Boehringer Ingelheim	Kinase inhibitor, targets EGFR
Alectinib	Alecensa	NSCLC	Genentech	Kinase inhibitor, targets ALK
Altretamine	Hexalen	Ovarian cancer	Eisai	Alkylating agent
Anastrozole	Anastrozole	Breast cancer	Various	Non-steroidal aromatase inhibitor
Axitinib	Inlyta	RCC	Pfizer	Kinase inhibitor
Bexarotene	Bexarotene	CTCL	Various	Retinoid
Bicalutamide	Bicalutamide	Prostate cancer	Various	Androgen receptor inhibitor
Bosutinib	Bosulif	CML	Pfizer	Kinase inhibitor
Brigatinib	Alunbrig	NSCLC	ARIAD Pharmaceuticals	Kinase inhibitor, targets ALK
Cabozantinib	Cabometyx	RCC	Exelixis	Kinase inhibitor
Capecitabine	Capecitabine	CRC, breast cancer	Various	Nucleoside metabolic inhibitor
Ceritinib	Zykadia	NSCLC	Novartis	Kinase inhibitor, targets ALK
Chlorambucil	Leukeran	Hematologic malignancies	Aspen Global	Bifunctional alkylating agent of the nitrogen mustard type
Cobimetinib fumarate	Cotellic	Melanoma	Genentech	Kinase inhibitor
Crizotinib	Xalkori	NSCLC	Pfizer	Kinase inhibitor, targets ROS1
Cyclophosphamide	Cyclophosphamide	Various	Various	Alkylating agent
Dabrafenib	Tafinlar	Melanoma	Novartis	Kinase inhibitor
Dasatinib	Sprycel	ALL, CML	Bristol-Myers Squibb	Kinase inhibitor, targets BCR-ABL
Eltrombopag olamine	Promacta	Chronic ITP	Novartis	Thrombopoietin receptor agonist
Enasidenib	Idhifa	AML	Celgene	IDH-2 inhibitor
Enzalutamide	Xtandi	Prostate cancer	Astellas Pharma	Androgen receptor inhibitor
Erlotinib	Tarceva	NSCLC, pancreatic cancer	OSI	Kinase inhibitor
Estramustine	Emcyt	Prostate cancer	Pharmacia and Upjohn	Antimicrotubule agent
Etoposide	Etoposide	Various	Various	Topoisomerase inhibitor
Everolimus	Afinitor	Various	Novartis	Kinase inhibitor
Exemestane	Exemestane	Breast cancer	Various	Aromatase inhibitor
Finasteride	Finasteride	Prostate cancer	Various	5-alpha reductase inhibitor
Flutamide	Flutamide	Prostate cancer	Various	Non-steroidal antiandrogen
Gefitinib	Iressa	NSCLC	AstraZeneca	Tyrosine kinase inhibitor
Hydroxyurea	Hydroxyurea	Various	Various	Antimetabolite
Ibrutinib	Imbruvica	MCL, WM, CLL, SLL, MZL, cGVHD	Pharmacyclics/Janssen Biotech	Bruton's tyrosine kinase inhibitor
<i>Note.</i> NSCLC = non-small cell lung cancer; RCC = renal cell carcinoma; CTCL = cutaneous T-cell lymphoma; CML = chronic myeloid leukemia; CRC = colorectal cancer; ALL = acute lymphoblastic leukemia; ITP = idiopathic thrombocytopenic purpura; AML = acute myelogenous leukemia; MCL = mantle-cell lymphoma; WM = Waldenström's macroglobulinemia; CLL = chronic lymphocytic leukemia; SLL = small lymphocytic lymphoma; MZL = marginal zone lymphoma; cGVHD = chronic graft-vs.-host disease; FL = follicular lymphoma; GIST = gastrointestinal stromal tumor; HCC = hepatocellular carcinoma; MF = myelofibrosis; PCV = polycythemia vera; pNET = primitive neuroectodermal tumor. Information from FDA.gov.				

Appendix. Oral Agents Used in the Treatment of Cancer (cont.)				
Generic name	Brand name	Disease	Manufacturer	Mechanism of action
Idelalisib	Zydelig	CLL, FL, SLL	Gilead	Kinase inhibitor
Imatinib mesylate	Imatinib mesylate	Various	Various	Tyrosine kinase inhibitor
Ixazomib	Ninlaro	Multiple myeloma	Takeda/Millennium	Proteasome inhibitor
Lapatinib	Tykerb	Breast cancer	Novartis	Kinase inhibitor, targets HER2
Lenalidomide	Revlimid	Multiple myeloma	Celgene	Immunomodulatory drug
Lenvatinib mesylate	Lenvima	Renal cell cancer, differentiated thyroid cancer	Eisai	Kinase inhibitor
Letrozole	Letrozole	Breast cancer	Various	Non-steroidal aromatase inhibitors
Leucovorin	Leucovorin	Various	Various	Folic acid analogue
Lomustine	Gleostine	Various	Corden Pharma	Alkylating agent
Megestrol acetate	Megestrol acetate	Various	Various	Synthetic progestin
Melphalan	Melphalan	Multiple myeloma, epithelial ovarian carcinoma	Various	Nitrogen mustard analogue
Mercaptopurine	Mercaptopurine	ALL	Various	Nucleoside metabolic inhibitor
Mesna	Mesna	Ifosfamide-induced hemorrhagic cystitis (prophylactic)	Various	Cytoprotective agent
Methotrexate	Methotrexate	Various	Various	Antimetabolite
Midostaurin	Rydapt	AML	Novartis	Multitargeted inhibitor of multiple kinases
Neratinib	Nerlynx	Breast cancer	Puma Biotechnology	Kinase inhibitor, targets HER2
Nilotinib	Tasigna	Ph+ CML	Novartis	Kinase inhibitor
Nilutamide	Nilutamide	Prostate cancer	Various	Non-steroidal antiandrogen
Niraparib	Zejula	Gynecologic cancers	Tesaro	PARP inhibitor
Olaparib	Lynparza	Gynecologic cancers	AstraZeneca	PARP inhibitor
Osimertinib	Tagrisso	NSCLC	AstraZeneca	Kinase inhibitor, targets T790M
Palbociclib	Ibrance	Breast	Pfizer	Kinase inhibitor, targets CDK4/6
Panobinostat	Farydak	Multiple myeloma	Novartis	HDAC inhibitor
Pazopanib	Votrient	RCC, soft-tissue sarcoma	GlaxoSmithKline	Kinase inhibitor
Pomalidomide	Pomalyst	Multiple myeloma	Celgene	Thalidomide analogue
Ponatinib	Iclusig	CML, ALL	ARIAD Pharmaceuticals	Kinase inhibitor
Procarbazine	Matulane	Hodgkin lymphoma	Leadiant Biosciences	Alkylating agent
Raloxifene	Evista	Breast cancer, osteoporosis	Eli Lilly	Estrogen agonist/antagonist
Regorafenib	Stivarga	CRC, GIST, HCC	Bayer	Kinase inhibitor
Ribociclib	Kisqali	Breast	Novartis	Kinase inhibitor, targets CDK4/6
<i>Note.</i> NSCLC = non-small cell lung cancer; RCC = renal cell carcinoma; CTCL = cutaneous T-cell lymphoma; CML = chronic myeloid leukemia; CRC = colorectal cancer; ALL = acute lymphoblastic leukemia; ITP = idiopathic thrombocytopenic purpura; AML = acute myelogenous leukemia; MCL = mantle-cell lymphoma; WM = Waldenström's macroglobulinemia; CLL = chronic lymphocytic leukemia; SLL = small lymphocytic lymphoma; MZL = marginal zone lymphoma; cGVHD = chronic graft-vs.-host disease; FL = follicular lymphoma; GIST = gastrointestinal stromal tumor; HCC = hepatocellular carcinoma; MF = myelofibrosis; PCV = polycythemia vera; pNET = primitive neuroectodermal tumor. Information from FDA.gov.				

Appendix. Oral Agents Used in the Treatment of Cancer (cont.)				
Generic name	Brand name	Disease	Manufacturer	Mechanism of action
Rucaparib	Rubraca	Ovarian cancer	Clovis Oncology	PARP inhibitor
Ruxolitinib	Jakafi	MF, PCV	Incyte	Kinase inhibitor
Sonidegib	Odomzo	Basal cell carcinoma	Novartis	Hedgehog pathway inhibitor
Sorafenib	Nexavar	Hepatocellular carcinoma, renal cell carcinoma, differentiated thyroid carcinoma	Bayer	Kinase inhibitor
Sunitinib	Sutent	GIST, RCC, pNET	Pfizer	Kinase inhibitor
Tamoxifen	Tamoxifen	Breast cancer	Various	Non-steroidal antiestrogen
Temozolomide	Temozolomide	Glioblastoma multiforme, anaplastic astrocytoma	Various	Alkylating agent
Thalidomide	Thalomid	Multiple myeloma	Celgene	Immunomodulatory agent
Thioguanine	Thioguanine	Acute nonlymphocytic leukemia	Aspen Global	Purine analogue
Topotecan	Hycamtin	Small cell lung cancer	Novartis	Topoisomerase inhibitor
Toremifene citrate	Fareston	Breast cancer	Kyowa Kirin	Estrogen agonist/antagonist
Trametinib	Mekinist	Melanoma	Novartis	Kinase inhibitor, targets MEK
Trifluridine and tipiracil	Lonsurf	CRC	Taiho Oncology	Nucleoside metabolic inhibitor plus thymidine phosphorylase inhibitor combination
Uridine triacetate	Vistogard	Fluorouracil or capecitabine overdose	Wellstat Therapeutics	Pyrimidine analogue
Vandetanib	Caprelsa	Thyroid cancer	Sanofi Genzyme	Kinase inhibitor
Vemurafenib	Zelboraf	Melanoma	Genentech	Kinase inhibitor
Venetoclax	Venclexta	CLL	AbbVie	BCL-2 inhibitor
Vismodegib	Erivedge	Basal cell carcinoma	Genentech	Hedgehog pathway inhibitor
Vorinostat	Zolinza	CTCL	Merck	HDAC inhibitor
<i>Note.</i> NSCLC = non-small cell lung cancer; RCC = renal cell carcinoma; CTCL = cutaneous T-cell lymphoma; CML = chronic myeloid leukemia; CRC = colorectal cancer; ALL = acute lymphoblastic leukemia; ITP = idiopathic thrombocytopenic purpura; AML = acute myelogenous leukemia; MCL = mantle-cell lymphoma; WM = Waldenström's macroglobulinemia; CLL = chronic lymphocytic leukemia; SLL = small lymphocytic lymphoma; MZL = marginal zone lymphoma; cGVHD = chronic graft-vs.-host disease; FL = follicular lymphoma; GIST = gastrointestinal stromal tumor; HCC = hepatocellular carcinoma; MF = myelofibrosis; PCV = polycythemia vera; pNET = primitive neuroectodermal tumor. Information from FDA.gov.				